Texas Capital Bank Wealth Management Services Inc Trims Position in Zoetis Inc. (NYSE:ZTS)

Texas Capital Bank Wealth Management Services Inc trimmed its position in Zoetis Inc. (NYSE:ZTSFree Report) by 2.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,331 shares of the company’s stock after selling 955 shares during the period. Texas Capital Bank Wealth Management Services Inc’s holdings in Zoetis were worth $7,565,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Forum Financial Management LP boosted its holdings in Zoetis by 0.8% in the fourth quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after acquiring an additional 56 shares in the last quarter. Prossimo Advisors LLC boosted its stake in Zoetis by 1.7% in the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after purchasing an additional 57 shares in the last quarter. River Street Advisors LLC grew its position in Zoetis by 3.4% during the 4th quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after purchasing an additional 58 shares during the last quarter. Perigon Wealth Management LLC increased its stake in Zoetis by 0.3% during the 4th quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock valued at $4,654,000 after purchasing an additional 59 shares in the last quarter. Finally, Revolve Wealth Partners LLC lifted its stake in shares of Zoetis by 5.0% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,281 shares of the company’s stock worth $253,000 after buying an additional 61 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS traded up $0.35 during trading on Friday, reaching $174.06. 1,999,468 shares of the company’s stock traded hands, compared to its average volume of 3,642,277. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. The firm has a market cap of $79.42 billion, a PE ratio of 33.54, a P/E/G ratio of 2.69 and a beta of 0.86. The company has a 50-day simple moving average of $164.65 and a 200-day simple moving average of $179.16.

Zoetis (NYSE:ZTSGet Free Report) last posted its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. During the same period last year, the firm earned $1.31 EPS. The company’s quarterly revenue was up 9.5% on a year-over-year basis. As a group, analysts predict that Zoetis Inc. will post 5.77 earnings per share for the current year.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the sale, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ZTS shares. Barclays cut their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Piper Sandler restated an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. The Goldman Sachs Group reduced their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, HSBC reduced their target price on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $211.75.

View Our Latest Stock Report on ZTS

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.